Key Highlights
- A mid-stage clinical study in China demonstrated that UBT251, co-developed by Novo Nordisk and United Laboratories, achieved average weight reduction reaching 19.7% over a 24-week period.
- The experimental therapy targets three key hormones—GLP-1, GIP, and glucagon—earning it the “triple G” designation.
- Participants experienced a favorable safety profile, with primarily mild to moderate digestive symptoms that diminished as treatment continued.
- The announcement follows closely behind CagriSema’s disappointing performance against Eli Lilly’s Zepbound in comparative testing.
- In March 2025, Novo Nordisk acquired worldwide development and commercialization rights to UBT251 for a deal valued at up to $2 billion.
On Tuesday, Novo Nordisk and United Laboratories International unveiled encouraging data from their investigational obesity medication UBT251, which delivered average weight reduction of up to 19.7% during a Phase 2 clinical study in China.
The clinical investigation spanned 24 weeks, evaluating various weekly injection dosages of UBT251 against a control group in Chinese participants classified as overweight or obese.
Participants entered the study with an average starting weight of 92.2 kg. Those receiving placebo experienced only 2.0% weight reduction during the equivalent timeframe.
In addition to significant weight reduction, trial participants demonstrated notable improvements across several health markers including waist measurements, glucose metabolism, and cardiovascular pressure readings when compared to the control cohort.
Safety data revealed the medication was generally well-received by participants. Digestive system-related adverse events remained in the mild to moderate range and showed progressive reduction throughout the study duration.
Researchers describe UBT251 as a “triple G” medication due to its mechanism of action on three distinct hormones: GLP-1, GIP, and glucagon. This multi-target approach differentiates it from existing single-pathway medications such as Wegovy and Zepbound.
The GLP-1 receptor activation controls hunger signals. GIP receptor engagement assists with both appetite regulation and glucose management. Glucagon receptor activity helps maintain stable blood sugar levels.
Competitive Landscape Analysis
The positive trial outcomes arrive during a challenging period for Novo Nordisk. Just 24 hours prior, the pharmaceutical giant disclosed that its CagriSema compound produced 23% weight reduction across 84 weeks — yet underperformed against Eli Lilly’s tirzepatide, which reached 25.5% in direct comparison testing.
Novo Nordisk’s share price declined 3.10% following the CagriSema data release.
United Biotechnology, the division responsible for conducting the Chinese clinical study, intends to advance UBT251 into Phase 3 trials with Chinese patient populations based on these encouraging findings.
Meanwhile, Novo Nordisk has independently launched its own international clinical investigation of UBT251, examining various dosing regimens in approximately 330 participants for a duration extending to 28 weeks. Data from this global study is anticipated to arrive in 2027.
The pharmaceutical company also has plans to initiate a Phase 2 clinical trial focused on Type 2 diabetes patients before year-end.
Strategic Acquisition Details
Novo Nordisk obtained worldwide development and marketing rights to UBT251 during March 2025 through a licensing arrangement with United Laboratories potentially worth $2 billion. Under the agreement’s terms, Novo receives exclusive authority to develop, produce, and market UBT251 across all global territories excluding mainland China, Hong Kong, Macau, and Taiwan — these regions remain under United Biotechnology’s control.
This transaction represents one of multiple strategic partnerships Novo Nordisk has pursued recently to strengthen its developmental pipeline. The company also attempted to acquire American biotech startup Metsera, though ultimately lost that competitive acquisition process to Pfizer.
Martin Holst Lange, Novo Nordisk’s Chief Scientific Officer, stated the company feels “very encouraged” by the Chinese clinical data and considers it validation of UBT251’s therapeutic potential.
International trial outcomes for UBT251 are projected to become available in 2027.
